The field of bone density assessment is undergoing its most significant transformation in over a decade, driven by a convergence of portable imaging technology, artificial intelligence (AI) algorithms, and a renewed clinical focus on fracture prevention beyond traditional dual-energy X-ray absorptiometry (DXA). At the recent Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), held in Toronto, industry leaders and academic researchers presented early data on novel screening modalities, while regulatory agencies signaled a shift toward approving therapies that target bone quality rather than solely density. These developments come against a backdrop of aging global populations, with the International Osteoporosis Foundation estimating that one in three women and one in five men over age 50 will experience a fragility fracture in their remaining lifetime.

Portable ultrasound and quantitative CT gain clinical traction

For decades, central DXA of the hip and spine has remained the gold standard for diagnosing osteoporosis, defined by a T-score of -2.5 or lower. However, access barriers—particularly in rural and low-income regions—have prompted a surge in interest for point-of-care devices. Several companies showcased next-generation radiofrequency echographic multi-spectrometry (REMS) units, which use handheld ultrasound probes to measure bone density at the femoral neck and lumbar spine without ionizing radiation. A multicenter study presented at ASBMR, involving 4,800 postmenopausal women across Europe and Asia, demonstrated that REMS-based fracture risk prediction was non-inferior to DXA for major osteoporotic fractures over a five-year follow-up.

Concurrently, opportunistic screening using routine computed tomography (CT) scans is moving from research novelty to practical implementation. Algorithms that automatically analyze abdominal CT images—originally obtained for unrelated indications such as kidney stones or aortic aneurysm screening—can now generate volumetric bone mineral density (vBMD) measurements at the lumbar spine. Dr. Elena Rodriguez, a radiologist at the University of California, San Francisco, noted in a press briefing, “We are seeing a paradigm where every CT scan becomes a potential osteoporosis screen without additional cost or radiation. The challenge is not technical accuracy but integrating these incidental findings into primary care workflows.” Several health systems in the United States and Japan have begun piloting automated flagging of low vBMD in radiology reports, with early data suggesting a 30% increase in osteoporosis diagnosis rates.

AI-driven fracture risk models move beyond T-scores

The traditional reliance on T-scores is being questioned by a growing body of evidence that bone density alone explains only a fraction of fracture risk. In 2025, the Fracture Risk Assessment Tool (FRAX) remains widely used, but its limitations—including a lack of adjustment for falls history and diabetes severity—have led to the development of machine learning models that integrate imaging biomarkers, clinical variables, and even genomic data. A notable presentation from the University of Sheffield’s Metabolic Bone Centre described a deep learning model trained on 12,000 DXA scans combined with electronic health records. The model outperformed FRAX by 14% in predicting hip fractures within 10 years, particularly in patients with type 2 diabetes and chronic kidney disease, populations where DXA often underestimates risk due to altered bone material properties.

Dr. Marcus Chen, an endocrinologist at the National University of Singapore, commented, “We are moving toward a precision medicine approach where ‘bone density’ is just one input. The next generation of risk calculators will incorporate trabecular bone score, cortical porosity from high-resolution peripheral quantitative CT (HR-pQCT), and even serum biomarkers like sclerostin. The regulatory path for these AI tools, however, remains fragmented, with the FDA and EMA requiring prospective validation before clinical adoption.”

Therapeutic pipeline: targeting bone quality and anabolic combinations

On the pharmaceutical front, the past six months have seen notable regulatory activity. The FDA approved a new subcutaneous formulation of romosozumab, a monoclonal antibody that inhibits sclerostin, offering an every-two-month dosing schedule that improves adherence compared to the monthly injection. More significantly, phase 3 trial results for a novel oral cathepsin K inhibitor—previously abandoned by Merck due to cardiovascular safety concerns—were resurrected by a smaller biotech firm with a modified molecular structure. The trial, enrolling 3,200 patients with osteopenia, showed a 38% reduction in vertebral fractures without an increase in cardiovascular events or atypical femoral fractures over a 24-month period. Analysts view this as a potential game-changer, as oral anabolic agents have been a long-sought goal.

However, the most discussed topic at the conference was the emerging role of sequential therapy. Current guidelines recommend anabolic agents (teriparatide or romosozumab) as first-line for very high-risk patients, followed by antiresorptive agents (bisphosphonates or denosumab) to maintain gains. New data from the ongoing VERITY trial suggest that transitioning directly from romosozumab to denosumab produces a 12% greater increase in hip bone density at year three compared to the traditional anabolic-to-bisphosphonate sequence. Dr. Sarah Whitfield, a bone pharmacologist at the University of Oxford, cautioned, “We need to be careful about interpreting density gains as surrogate endpoints. Fracture outcomes remain the ultimate measure, and long-term safety data for combination and sequential regimens are only now maturing.”

Policy and reimbursement: shifting toward fracture liaison services

Beyond technology and drugs, a major trend is the expansion of fracture liaison services (FLS)—coordinated care models that identify, evaluate, and treat patients over age 50 who present with a fragility fracture. A meta-analysis published inThe Lancet Healthy Longevityin early 2025 found that FLS programs reduce subsequent fracture risk by 22% and mortality by 18% within two years. In response, the Centers for Medicare & Medicaid Services (CMS) in the U.S. has proposed a new bundled payment code for FLS, effective October 2025, which would reimburse a comprehensive bone health assessment—including DXA, vertebral fracture assessment, and falls risk screening—for six months post-fracture. Similar initiatives are underway in the UK’s National Health Service, which has committed to universal FLS coverage by 2027.

Nevertheless, challenges persist. A global survey of 1,200 primary care physicians, released by the International Osteoporosis Foundation, revealed that 58% still do not routinely order bone density testing for patients on long-term glucocorticoid therapy, a major secondary cause of osteoporosis. Moreover, disparities in access to DXA remain stark: while Japan has 37 scanners per million population, many sub-Saharan African countries have fewer than one. Portable and AI-based solutions may help bridge this gap, but their reimbursement pathways are unclear in low-resource settings.

Expert outlook: a decade of convergence

Dr. Rajesh Kumar, a clinical densitometrist and advisor to the International Society for Clinical Densitometry, summarized the prevailing sentiment: “Bone density is not dying; it is evolving. The field is moving from a single number to a multidimensional risk profile. Within five years, I expect that routine clinical practice will combine a DXA scan, a REMS ultrasound for home monitoring, and an AI-generated risk report that updates dynamically with electronic health data. The regulatory and payment systems are lagging, but the scientific foundation is solid.”

As the global population ages and the economic burden of fractures—estimated at $180 billion annually worldwide—continues to climb, the urgency for earlier and more accurate bone density assessment has never been greater. The industry’s response, characterized by technological convergence and therapeutic innovation, suggests that the next decade will redefine what it means to measure and treat skeletal health. For clinicians, payers, and patients alike, the message is clear: the era of one-size-fits-all bone density testing is ending, replaced by a more nuanced, integrated, and ultimately more effective approach to preventing fractures.